The abuse of the amphetamine analog, 3,4-methylenedioxymethamphetamine (MDMA), continues as a significant public health problem. Treatment of rats with MDMA destroys brain serotonergic nerve terminals which is accompanied by a long-lasting decrease in tryptophan hydroxylase (TPH) activity. The mechanism by which this neuronal damage occurs remains unknown. Interestingly, MDMA causes a biphasic response in the central serotonergic system. The first phase consists of a rapid decrease in the cerebral TPH activity which is detected within 15 min of drug administration. This early phase (phase l) is reversed by incubating the enzyme in vitro under reducing conditions. In the second phase, a decrease in TPH activity (phase 2) is observed days after MDMA administration and last for extended periods of time; in contrast to phase l, phase 2 cannot be reversed by reducing conditions. The long-lasting change in TPH activity is associated with MDMA-induced neurotoxicity. Evidence presented in this proposal suggests that TPH protein undergoes an initial reversible transformation during phase 1, with other possible transformations during an intermediate transitional stage occurring prior to TPH protein destruction due to neuronal damage (phase 2). The phase l decrease in TPH activity is caused by oxidative conditions which are proposed to predispose the serotonergic neuron to permanent neuronal (damage. Since TPH is sensitive to MDMA-induced oxidative alterations present in the serotonergic system, we propose to use this enzyme as a probe to monitor and characterize this phenomenon. The characterization of these oxidative conditions will be achieved by identifying the different stages of TPH protein transformation by correlating the MDMA-induced decrease in TPH activity with its protein concentration and with recovery of enzyme activity induced by reducing conditions. The MDMA-generated oxidative conditions will be further characterized by studying the effects of different free radical scavengers on the three stages of TPH transformation. The role of glutathione as a protective system in the serotonergic system will also be investigated. Finally, the reactive substances generated by MDMA will be investigated by studying the alterations of the TPH protein isolated during the different stages by immunoprecipitation and electrophoresis. This study should assist in identifying the biochemical alterations induced by MDMA and similar amphetamine analogs and their impact on brain proteins.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004222-10
Application #
2117087
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1986-09-01
Project End
1998-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
10
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Vieira-Brock, Paula L; Andrenyak, David M; Nielsen, Shannon M et al. (2013) Age-related differences in the disposition of nicotine and metabolites in rat brain and plasma. Nicotine Tob Res 15:1839-48
McFadden, Lisa M; Stout, Kristen A; Vieira-Brock, Paula L et al. (2012) Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse 66:240-5
McFadden, Lisa M; Hunt, Madison M; Vieira-Brock, Paula L et al. (2012) Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations. Drug Alcohol Depend 126:87-94
McFadden, Lisa M; Hadlock, Greg C; Allen, Scott C et al. (2012) Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther 340:295-303
German, Christopher L; Hanson, Glen R; Fleckenstein, Annette E (2012) Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. J Neurochem 123:288-97
Hanson, G R; Hoonakker, A J; Alburges, M E et al. (2012) Response of limbic neurotensin systems to methamphetamine self-administration. Neuroscience 203:99-107
Hadlock, Gregory C; Nelson, Chad C; Baucum 2nd, Anthony J et al. (2011) Ex vivo identification of protein-protein interactions involving the dopamine transporter. J Neurosci Methods 196:303-7
Vieira-Brock, Paula L; Miller, Eleanor I; Nielsen, Shannon M et al. (2011) Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879:3465-74
Frankel, Paul S; Hoonakker, Amanda J; Alburges, Mario E et al. (2011) Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia. J Pharmacol Exp Ther 336:809-15
Hadlock, Gregory C; Webb, Katy M; McFadden, Lisa M et al. (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530-6

Showing the most recent 10 out of 101 publications